According to the Complaint, Analogic Corporation ("Analogic" or the "Company") is company that focuses on healthcare and security technology.
On April 10, 2018, Analogic’s Board of Directors (the “Board” or the “Individual Defendants”) caused the Company to enter into an Agreement and Plan of Merger (the “Merger Agreement”) with Altaris Capital Partners, LLC. Pursuant to the terms of the Merger Agreement, each share of Company common stock will be converted into the right to receive $84.00 in cash (the “Merger Consideration”). Upon completion of the Merger, AC Merger Sub, Inc. will merge with and into Analogic, with Analogic surviving as a privately-held company and will cease to be listed on any public market.
On May 2, 2018, Defendants filed a Preliminary Proxy Statement on Schedule 14A with the United States Securities and Exchange Commission in connection with the Proposed Transaction (the “Proxy”). The Complaint alleges that the Proxy omits certain material information with respect to the Proposed Transaction, which renders it false and misleading, in violation of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934.